

1 substituted for counterpart HN and F glycoprotein genes of  
2 HPIV3 to for said infectious, chimeric PIV particle.

1 143. The immunogenic composition of claim 142,  
2 wherein said recombinant PIV genome or antigenome further  
3 incorporates a full complement of mutations present in JS  
4 cp45, said full complement of mutations comprising i)  
5 substitutions specifying a replacement of His for Tyr<sub>942</sub>, Phe  
6 for Leu<sub>992</sub>, and Ile for Thr<sub>1558</sub> in the polymerase L protein;  
7 ii) substitutions specifying a replacement of Ala for Val<sub>96</sub>  
8 and Ala for Ser<sub>389</sub> in the N protein; iii) a substitution  
9 specifying a replacement of Thre for Ile<sub>96</sub> in the C protein;  
10 iv) substitution specifying an amino acid change in the F  
11 protein comprising a replacement of Val for Ile<sub>420</sub> or Thr for  
12 Ala<sub>450</sub>; v) substitutions specifying a replacement of Ala for  
13 Val<sub>384</sub> in the HN protein; vi) a substitution specifying a  
14 replacement of Thr for Pro<sub>199</sub> in the M protein; vii)  
15 mutations in a 3' leader sequence comprising a T to C change  
16 at a position corresponding to nucleotide 23 of JS cp45, a C  
17 to T change at nucleotide 24, a G to T change at nucleotide  
18 28, and a T to A change at nucleotide 45 of JS cp45; and  
19 viii) a mutation in an N gene start sequence comprising an A  
20 to T change at a position corresponding to nucleotide 62 of  
21 JS cp45.

#### REMARKS

With entry of this amendment claims 1-94 and 96-128 are pending in the application. By this amendment claim 95 has been canceled without prejudice, claim 100 has been amended, and claims 129-143 have been added for clarity. Support for the amendment to claim 100 and for new claims 129-143 is found throughout the original specification and original claims. Exemplary support in this context is provided at page 7, lines 11-27; page 9, line 28 to page 10, line 6; page 28, line 10 to page 29; line 25; page 32, line 9 to page 35, line 2; page 37, line 10 to page 42, line 23;

Table 8; and Examples IX-XII (pages 78-129). All of the amendments herein are fully supported by the specification, and no new matter has been added to the application. Entry of these amendments is respectfully requested.

Respectfully submitted,

Dated: 1/22/99, 1999 By: Jeffrey V. King  
Reg. No. 38,515

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
(206) 467-9600

JJK/kg

17634\3\2\restrict.req